|
Clinical and tumour characteristics
|
Origin
|
Combined both study groups
|
|---|
|
Eritrean
|
Sudanese
|
|---|
|
n
|
%
|
n
|
%
|
n
|
%
|
|---|
|
Histologic type
|
IDCNST
|
89
|
76.7%
|
492
|
87.9%
|
581
|
85.9%
|
|
ILC
|
11
|
9.5%
|
18
|
3.2%
|
29
|
4.3%
|
|
others
|
16
|
13.8%
|
50
|
8.9%
|
66
|
9.8%
|
|
Pathologic tumour size
|
pT1
|
23
|
19.8%
|
82
|
15.5%
|
105
|
16.3%
|
|
pT2
|
48
|
41.4%
|
248
|
47.0%
|
296
|
46.0%
|
|
pT3
|
37
|
31.9%
|
118
|
22.3%
|
155
|
24.1%
|
|
pT4
|
8
|
6.9%
|
80
|
15.2%
|
88
|
13.7%
|
|
LN involvement
|
pN0
|
72
|
62.1%
|
198
|
47.3%
|
270
|
50.5%
|
|
pN1(1–3)
|
15
|
12.9%
|
86
|
20.5%
|
101
|
18.9%
|
|
pN2(3–9)
|
16
|
13.8%
|
78
|
18.6%
|
94
|
17.6%
|
|
pN3(>9)
|
13
|
11.2%
|
57
|
13.6%
|
70
|
13.1%
|
|
Grading
|
GI
|
10
|
8.6%
|
20
|
3.6%
|
30
|
4.4%
|
|
GII
|
46
|
39.7%
|
306
|
54.6%
|
352
|
52.1%
|
|
GIII
|
60
|
51.7%
|
234
|
41.8%
|
294
|
43.5%
|
|
LVI
|
NO
|
44
|
37.9%
|
264
|
46.9%
|
308
|
45.2%
|
|
unknown
|
6
|
5.1%
|
111
|
19.8%
|
117
|
17.3%
|
|
YES
|
56
|
48.3%
|
185
|
15.2%
|
102
|
35.5%
|
|
ER
|
ER negative.
|
59
|
50.9%
|
308
|
55.0%
|
367
|
54.3%
|
|
ER positive.
|
57
|
49.1%
|
252
|
45.0%
|
309
|
45.7%
|
|
PR
|
PR negative
|
69
|
59.5%
|
346
|
61.8%
|
415
|
61.4%
|
|
PR positive
|
47
|
40.5%
|
214
|
38.2%
|
261
|
38.6%
|
|
HR
|
HR positive
|
57
|
49.1%
|
257
|
45.9%
|
314
|
46.4%
|
|
HR negative
|
59
|
50.9%
|
303
|
54.1%
|
362
|
53.6%
|
|
HER2
|
negative
|
82
|
70.7%
|
296
|
71.3%
|
378
|
71.2%
|
|
positive
|
34
|
29.3%
|
119
|
28.7%
|
153
|
28.8%
|
| |
Missing
|
0
|
0
|
147
|
–
|
147
|
–
|
|
IHC based breast cancer subtype
|
Luminal A-like
|
43
|
37.1%
|
153
|
36.9%
|
196
|
36.9%
|
|
Luminal B-like
|
14
|
12.1%
|
54
|
13.0%
|
68
|
12.8%
|
|
HER2 enriched
|
20
|
17.2%
|
65
|
15.7%
|
85
|
16.0%
|
|
TNBC
|
39
|
33.6%
|
143
|
34.5%
|
182
|
34.3%
|
-
IDCNST invasive ductal carcinoma, no special type, ILC invasive lobular carcinoma, TNBC Triple negative Breast cancer
